FDA warned Getsch+Hiller about unapproved reusable laparoscopic tips and missing quality records at its German plant.
What happened
FDA inspected the Tuttlingen, Nendingen, Germany facility from July 18, 2022 through July 21, 2022. It found no design history file for reusable-tip laparoscopic instruments intended for the U.S., raw materials used without incoming acceptance, and reusable tips marketed beyond the single-use clearance in K171523.
What FDA found
FDA says the company did not establish a design history file for its Class II monopolar laparoscopic instruments with reusable tips intended for the U.S. market.
21 CFR 820.30(j)FDA says raw materials that had not gone through incoming acceptance were labeled as approved and staged next to approved materials used to make devices.
21 CFR 820.80(b)FDA says the monopolar laparoscopic instruments lack an approved premarket approval application or investigational device exemption.
section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)FDA says the company marketed reusable tip inserts after its clearance covered only single-use tips, a significant change requiring a new 510(k).
section 502(o) of the Act, 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k); 21 CFR 807.81(a)(3)
What FDA wants
FDA asks the company to respond in writing within 15 business days with specific steps, documentation of corrections and corrective actions, and a timetable for any planned actions.
Who should pay attention
- U.S. hospitals and surgical centers using laparoscopic instruments
- distributors and importers of German medical devices
- device quality teams managing design and incoming acceptance records
This is a summary. Read the original letter on fda.gov.